8-K: DSS Converts $12 Million Debt to Equity in Impact Biomedical

DSS, Inc. has converted an outstanding $12 million revolving promissory note owed by Impact Biomedical Inc. into 31,939,778 shares of Impact Biomedical common stock, fully settling the debt.

Summary

• DSS, Inc. (Lender) entered into a Debt Conversion Agreement with Impact Biomedical Inc. (Borrower) on July 21, 2025.
• The agreement settles an outstanding revolving promissory note, originally issued on March 31, 2023, with a principal amount of $12,000,000.
• The original note was amended on January 18, 2024, to extend the maturity date to September 30, 2023, eliminate the advance feature, establish specific repayment terms, and adjust the interest rate to WSJ Prime + 0.5%.
• In exchange for settling all outstanding debt, including financial or operational support provided by DSS or its affiliates between June 21, 2025, and the closing date, DSS received 31,939,778 shares of Impact Biomedical Inc.'s freely tradeable common stock.
• The issuance of these shares constitutes full and final satisfaction of all amounts owed to DSS.

Sentiment

Score: 4

Explanation: The conversion of debt to equity, while resolving an outstanding obligation, typically indicates the borrower's inability to repay in cash, which is a negative signal. For the lender (DSS), it shifts risk from a fixed-income claim to an equity stake, which is inherently more volatile. While it clears the books, it's not an ideal outcome compared to cash repayment.

Positives

• DSS has fully settled a $12,000,000 outstanding debt owed by Impact Biomedical Inc., converting it into equity.
• Receiving freely tradeable common stock provides DSS with liquidity potential in the future.
• The conversion eliminates a potentially non-performing or difficult-to-collect debt from DSS's books.

Negatives

• The conversion of debt to equity suggests Impact Biomedical Inc. may have faced challenges in repaying the debt in cash.
• DSS is now exposed to the equity risk of Impact Biomedical Inc., meaning the value of the shares received could fluctuate.
• The original note's maturity date was extended to September 30, 2023, but the conversion happened in July 2025, indicating a prolonged inability to collect cash.

Risks

• The value of the 31,939,778 shares of Impact Biomedical Inc. common stock received by DSS is subject to market fluctuations and the performance of Impact Biomedical Inc.
• There is an inherent risk associated with converting a debt instrument into equity, as it shifts the lender's position from a creditor with a fixed claim to an equity holder with a residual claim.

Future Outlook

The filing primarily addresses a past debt settlement and does not provide explicit forward-looking statements or guidance regarding future operations or financial performance for either DSS or Impact Biomedical Inc.

Management Comments

• Jason Grady signed the report as Interim Chief Executive Officer of DSS, INC.

Industry Context

This debt-to-equity conversion is a common mechanism used in financial restructuring, particularly when a borrower faces liquidity challenges and cannot meet its debt obligations. It allows the lender to recover value by taking an equity stake, potentially benefiting from future growth, while the borrower reduces its debt burden. This is often seen in smaller or developing companies, especially in sectors like biomedical where R&D costs are high and profitability may be delayed.

Comparison to Industry Standards

• Debt-to-equity conversions are a standard financial restructuring tool, often employed when a company's cash flow is insufficient to service its debt.
• The specific terms, such as the conversion ratio (debt amount to shares received), would typically be evaluated against Impact Biomedical's valuation and market conditions at the time of conversion, though this information is not provided in the filing.
• Comparable situations might involve venture debt firms or strategic investors converting convertible notes into equity in early-stage or growth companies that are not yet profitable.

Stakeholder Impact

• Shareholders of DSS: The conversion removes a potentially problematic debt from the balance sheet but replaces it with an equity stake in another company, introducing new market risk. The value of their investment will now be indirectly tied to Impact Biomedical's performance.
• Shareholders of Impact Biomedical Inc.: The conversion dilutes existing shareholders by issuing new shares to DSS, but it also significantly reduces the company's debt burden, potentially improving its financial stability and outlook.

Next Steps

• DSS will hold 31,939,778 shares of Impact Biomedical Inc. common stock, which may be sold in the market in the future.

Key Dates

Recommendation

The conversion of a significant debt into equity resolves a past financial obligation for DSS, removing a potential overhang. However, it also means DSS is now exposed to the equity risk of Impact Biomedical Inc., whose financial health previously necessitated this conversion. Without more information on Impact Biomedical's current valuation, prospects, or DSS's strategic intent with these shares, a "hold" recommendation is prudent. It's a neutral event that clears a liability but introduces new, unquantified equity exposure.

Keywords

Debt Conversion, Equity Conversion, Promissory Note, Revolving Note, Impact Biomedical, DSS, Financial Restructuring, Share Issuance, Corporate Finance, SEC Filing, 8-K